Datar Cancer Genetics Wins FDA Clearance for Dual DNA+RNA Comprehensive Genomic Profiling Assay

Datar Cancer Genetics has secured a landmark US FDA clearance for CellDx-Tissue, its comprehensive genomic profiling (CGP) assay designed for solid tumor analysis. The clearance marks a significant regulatory milestone for the company and for the broader oncology genomics market, as CellDx-Tissue is distinguished by its simultaneous interrogation of both DNA and RNA from tumor tissue — a dual-analyte approach that positions it competitively among next-generation sequencing panels seeking clinical adoption in the United States.

The Technology

CellDx-Tissue represents a meaningful step forward in the architecture of comprehensive genomic profiling assays. By incorporating both DNA and RNA analysis within a single workflow, the platform expands the range of genomic alterations that can be detected compared to DNA-only panels. RNA-based analysis adds the ability to identify gene fusions, splice variants, and expression-level alterations that would otherwise be invisible to a purely DNA-centric approach. For oncology genomics professionals, this matters because many clinically actionable drivers — particularly in lung, thyroid, and soft tissue cancers — are fusion events that require RNA sequencing to detect with high sensitivity and specificity. The integration of both analyte types into one assay reduces the need for reflex testing and streamlines the diagnostic pathway for patients with solid tumors.

Clinical Context

FDA clearance for a CGP assay carries substantial weight in the United States market. It signals that the assay has met rigorous standards for analytical validity and provides a regulatory foundation for adoption within hospital systems, reference laboratories, and integrated health networks that require cleared or approved tests for reimbursement and clinical decision support. The solid tumor space remains one of the most active areas of oncology genomics, where tumor mutational burden, microsatellite instability, and a growing roster of targeted therapy biomarkers demand broad, reliable genomic characterization. CellDx-Tissue's clearance gives oncologists and molecular pathologists an additional validated tool for guiding treatment selection across a wide range of malignancies, and it extends Datar Cancer Genetics' clinical footprint into one of the world's most demanding regulatory environments.

What's Next

The clearance opens the door for Datar Cancer Genetics to pursue partnerships with US-based health systems, payers, and pharmaceutical companies running companion diagnostic programs. As the CGP market continues to consolidate around platforms that can deliver the broadest clinically actionable information from a single test run, the race to combine DNA and RNA profiling under regulatory approval will likely accelerate among competing vendors globally.

This clearance underscores a growing industry expectation that the next generation of oncology genomic tests will be defined not by what single analyte they interrogate, but by how comprehensively they characterize the full molecular landscape of a tumor in one standardized, regulatory-approved workflow.